Brexit Q&A: Where Do Notified Body, Authorized Representative Offices Need To Be?
Medtech regulatory service providers cannot afford to "wait and see" on the final outcome of Brexit. Questions such as the appropriate base of operations to serve device companies looking to sell into the UK and the EU are swirling. So how should the sector be covering its back? Medtech Insight spoke to John Adcock of Advena, a consultancy that serves as an authorized representative, to find out his views.
You may also be interested in...
The uncertainty over the UK position in Europe, on top of the questions surrounding many aspects of the implementation of the EU’s forthcoming medtech regulations, is making any efforts at planning difficult for many in the medtech sector. But indications are that the UK will be on board the EU medtech ship a while longer.
Updated medtech notified body figures from the European Commission always make headline news. But industry needs to see real appointments now, not a list of tricky-to-understand numbers.
Erik Hansson remains deputy head of devices in a move to the European Commission’s DG Sante from DG Grow. He now answers to a newly appointed devices head who shares a common educational background but whose recent pharmaceutical role may unsettle the devices industry.